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Remote ischaemic preconditioning and myocardial
protection
Ischaemia-reperfusion injury occurs during heart surgery
using cardiopulmonary bypass (CPB) and cardioplegic
arrest. Cardioplegic arrest allows the surgeon to oper-
ate on a motionless heart. While the heart is arrested,
there is no blood flow to the myocardium, which
makes it ischaemic and can cause myocardial damage.
When the blood circulation to the myocardium is
restored at the end of cardioplegic arrest, reperfusion of
the ischaemic myocardium induces further injury,
often more severe.
Remote ischaemic preconditioning (RIPC) is a poten-
tially protective phenomenon in which brief ischaemia
of one organ or tissue (for example, arm or leg) is
hypothesised to confer protection of another organ or
tissue (for example, heart) against a sustained ischaemia-
reperfusion insult [1-3]. Clinical benefits have been
reported in patients prior to primary percutaneous
coronary intervention (PCI) [4], in patients having
paediatric [5,6] or adult open heart surgery [7-14] and
during surgical repair of abdominal aortic aneurysm
[15]. However, not all studies of RIPC have reported
benefits [2,16,17].
A key challenge in interpreting the variation in
findings has been a lack of evidence about mecha-
nisms underpinning the effects of RIPC. In the
absence of such evidence, it is difficult to know what
other aspects of the treatment of patients (for
example, choice of anaesthetic [18] and method of
myocardial protection) may facilitate or inhibit the
effect of RIPC and what aspects of the preconditioning
stimulus are critical (for example, number and duration
of cycles of ischaemia, timing in relation to onset of
myocardial ischaemia, and applying the stimulus after
rather than before sternotomy). It has been suggested
that a sensation of pain (nociceptive preconditioning)
may also be important [19,20].
The study population is another factor that may affect
the effect of RIPC. For example, it has been suggested
that the hearts of patients with ischaemic heart disease
needing coronary artery bypass graft (CABG) surgery
may already be pre-conditioned by virtue of the disease.
This view leads to the hypothesis that the effects of
RIPC should be greater in patients without ischaemic
heart disease but still undergoing CPB and cardioplegic
arrest, for example, patients having heart valve surgery
[12-14]. Nevertheless, the evidence that has accrued
to date from these proof-of-concept clinical studies in
adult cardiac surgery has led to a large multicentre
randomized clinical trial in patients having coronary
artery bypass graft (CABG) surgery with or without
valve surgery [21].Possible mechanisms underlying cardioprotection by
remote ischaemic preconditioning
Although the mechanism by which a preconditioning
stimulus in a patient’s limb confers protection to the heart
is unknown [22], the preconditioned limb is presumed to
transmit a signal to the heart, which, in turn, is presumed
to trigger changes in the myocardium that eventually
result in protection. Possible mechanisms have been
proposed based on experimental models [1,23]. For
example, it has been suggested that the ‘signalling’
mechanism between the remotely preconditioned
organ/tissue and the heart could involve humoral and
neural factors [24] or metabolites (for example, adenosine,
bradykinin and opioids) [25-29]. More recent evidence
suggests the involvement of hydrophobic mediators
acting via PI3K/Akt-dependent pro-survival signalling [30].
There is also evidence that RIPC triggers an inflammatory
response [6].
Similarly, little is known about the changes in the target
tissue (myocardium) that are brought about by RIPC
before ischemia and reperfusion. Most studies that
have investigated changes in the myocardium have
done so after reperfusion. It has been suggested that
a signalling factor triggers intracellular signal transduction
mechanisms in the heart, which are similar to those
involved in cardiac ischaemic pre- and post-conditioning
[1]. These could include activation of pro-survival kinases
of the reperfusion injury salvage kinase (RISK) pathway,
which could protect the heart by inhibition of the
mitochondrial permeability transition pore (MPTP)
[1]. It is possible that a variety of other signalling
pathways involved in MPTP regulation [31] could also
be involved in RIPC-induced protection. A recent
experimental study [32] investigated the differential role
of mitogen-activated protein kinase pathways, which
suggested that the phosphorylation of p38MAPK,
Erk1/2 and JNK could be involved in RIPC. Experimental
evidence supports involvement of the mitochondrial
Ca2+-activated K+ channel [33]. A very recent observa-
tional clinical study reported that RIPC was associated
with changes in the phosphorylation of the signal
transducer and activator of transcription 5 (STAT5)
[11]. Most of these studies point to the mitochondria
as a potential target for inducing protection by RIPC.
We hypothesise that kinases involved in regulating the per-
meability of the MPTP are the mediators of RIPC-induced
cardioprotection. Therefore, these enzymes and related
signalling pathways will be monitored to identify the main
pathway(s) responsible.
A key difference that is likely to exist between RIPC
and cardiac pre- and post-conditioning stimuli (where
the heart is made ischaemic for short periods) is related
to changes in energy rich phosphates. Thus, RIPC is not
expected to trigger cardiac changes associated with
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build-up of ATP catabolites and lactate). However, a recent
experimental study in mice has demonstrated that RIPC is
associated with cardiac ischaemic stress and accumulation
of cardiac adenosine prior to index ischaemia [34]. This high-
lights the need to measure ischaemic-stress related metabo-
lites in the hearts of patients undergoing surgery using RIPC.Methods/Design
Aims and objectives
The overall aim of the trial is to investigate the cardiopro-
tective effect of RIPC in patients having CABG or aortic
valve replacement surgery. Specific objectives are:
1. To estimate the difference in myocardial injury
following CPB and cardioplegic arrest in groups of
participants exposed to RIPC or sham RIPC.
2. To test whether the effect of RIPC versus sham RIPC
differs in participants having CABG compared to
participants having aortic valve replacement.
3. To investigate a range of possible signalling
mechanisms that may underpin a cardioprotective
effect.
No RIPC represents standard clinical practice in the
two centres.Figure 1 Trial schema.Study design
This study is a two-centre randomised controlled trial in-
vestigating the effects of RIPC in two pathologies: patients
having isolated CABG with CPB and those having aortic
valve replacement surgery (AVR) with CPB. Participants
will be randomised to RIPC or control (sham RIPC), strati-
fied by surgical stratum. The randomization will be carried
out by a designated member of the research team. The
research nurse carrying out the intervention in the theatre
and collecting the intra-operative and post-operative
samples will not be involved in the data collection
(see below). Another research nurse blinded to the
allocation will do the post-operative data collection.
Other trial personnel, participants and clinicians will be
blinded to a participant’s random allocation. Figure 1
outlines the flow of trial participants in the study.Research approval
A favourable research ethics opinion has been granted
by the Harrow NRES Research Ethics Committee London
(reference 12/LO/1361).Study population and recruitment procedure
All patients referred for elective or urgent open-heart
surgery with CPB will form the target population and be
screened for trial eligibility. Male and female patients,
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CABG or AVR and who are willing to be followed-up and
provide written informed consent will be eligible. Patients
who have experienced cardiogenic shock or cardiac arrest,
suffer from significant peripheral arterial disease affecting
the upper limbs or have neither upper limb available
for the intervention, have pre-operative renal failure
(with a GFR <30 ml/min/1.73 m2) or have been taking
glibenclamide or nicorandil within 24 hours of surgery will
be considered ineligible. Patients who are participating in
other interventional studies are also ineligible. These
exclusion criteria are similar to the ones used by
other researchers who have investigated the effects of
RIPC [8,10].
All potential participants will be sent or given an
invitation letter and Patient Information Sheet (PIS)
(approved by the local Research Ethics Committee
(REC)) describing the study. The patient will have
time to read the PIS and to discuss their participation
with others outside the research team (for example,
relatives or friends) if they wish. Most patients will
have at least 24 hours to consider whether to participate
or not. In a few cases, this time interval may be as little as
12 hours or less, for example, for those patients admitted
for urgent surgery without prior notification to the waiting
list co-ordinator. Despite the short notice, it is important
to include these patients for the applicability of the
trial findings since about 40% of patients having cardiac
surgery are admitted as urgent cases. Such exceptions
were considered to be justified by the REC.
At the pre-assessment clinic or after admission to
the cardiac unit for their operation, patients will be
seen by a member of the local research team (study
clinician/research nurse) who will answer any questions,
confirm the patient’s eligibility and take written informed
consent if the patient decides to participate. A copy of the
consent form is provided in the Additional file 1.
A surgeon can decide not to randomise an otherwise
eligible patient but has to give a reason for doing so. The
trial screening log documents the reasons for ineligibility
and, where provided, the reasons why an eligible patient
declines to consent.
Randomisation
Random allocations, stratified by surgical stratum and
centre, will be generated by computer. Random treatment
allocations will be (a) blocked with varying block sizes to
ensure approximate balance in the number of participants
allocated to each group; (b) generated in advance of
starting the study; and (c) accessed using a secure, internet-
based randomization system to guarantee concealment
until a participant’s identity and eligibility is confirmed and
securely documented. Randomization will be carried out
after consent has been collected and before the operationby a designated member of the research team who will not
be involved in data collection.
Participants will be blinded because the intervention is
delivered in theatre and there will be no visible signs of
having had RIPC. The operating staff and data collectors
will be blinded because a research nurse, who will
have no further role in the trial, will deliver RIPC or
sham RIPC (see below).
Trial interventions
Remote ischaemic preconditioning (intervention)
A research nurse will apply the cuff for administering
RIPC under the operating cover, placing the cuff around
the participant’s upper arm, after induction of anaesthesia
and before sternotomy, CPB and cardioplegic arrest. RIPC
will be induced as described by others [8,10]. It will
comprise four 5 minute cycles of upper limb ischaemia,
induced by a blood pressure cuff inflated to 200 mmHg,
with an intervening 5 minutes of reperfusion by
deflating the cuff. For participants with systolic blood
pressure >185 mmHg, the cuff will be inflated at least
15 mmHg above the participant’s systolic blood pressure.
Sham remote ischaemic preconditioning (comparator)
A research nurse will position the cuff for administering
RIPC as for the intervention group, under the operating
cover and will squeeze the bulb with the air valve
opened, at the same intervals as in the intervention
group. This will ensure that all operating staff other than
the research nurse placing the cuff will perceive the cuff
to be inflated for all participants.
Both groups will have anaesthesia, sternotomy, CPB and
cardioplegic arrest applied in accordance with a standard
protocol. All patients received cold blood cardioplegia.
Complications of intervention
The only possible complication attributable to the interven-
tion is the onset of skin petechiae caused by cuff inflation.
In this circumstance, a participant’s allocation is likely to
become unblinded.
Study centres
This study is a two-centre, randomised controlled trial.
The two centres taking part are the Imperial College
Healthcare NHS Trust (ICHT) and University Hospitals
Bristol NHS Foundation Trust (UHBristol).
Quality control of intervention and study procedures
A manual will be developed describing in detail all aspects
of recruitment, randomization, interventions, data collec-
tion pertaining to blood and tissue sample collection and
CRF completion together with safety reporting. This
manual will be utilised to monitor adherence to procedural
steps. The times of each cuff inflation and deflation will
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intervention.
Primary outcome
The primary outcome will be myocardial injury, assessed
by measuring myocardial Troponin I in serum from
blood samples.
Secondary outcomes
The secondary outcomes will be obtained from data
collected from myocardial biopsies and blood samples.
Markers in myocardial biopsies
The degree of ischaemic stress (anaerobic metabolism)
associated with RIPC and cardioplegic arrest will be
determined in ventricular biopsies. The metabolites
that will be investigated in the ventricular biopsies
are creatine phosphate, ATP, ADP, AMP, IMP, inosine,
xanthine, hypoxanthine, adenosine, NAD+, lactate, alanine
and glutamate. In addition, markers of potential signalling
pathways that could be involved in RIPC will be
monitored [23]. These secondary outcomes will be
analysed in biopsies from the majority of participants,
with a subgroup (about ten per group) being used for
analyses of protein expression.
Expression of proteins implicated in RIPC protection in
experimental studies will be determined by characterising
the activation of intracellular kinases [35-37], the acti-
vation of the reperfusion injury salvage kinase (RISK)
pathway, and the survivor activating factor enhancement
(SAFE) pathway [38]. Gene expression for proteins that
are activated will also be determined. Recent technological
advances have provided new tools for screening and
characterisation of activated proteins including mass
spectrometry [39]. This is particularly important at the
level of post-translational modifications of proteins (for
example, phosphorylation), which are largely responsible
for regulation of protein activity and function [40,41].
Therefore, the cardiac phosphoproteome will be measured
in order to draw firm conclusions about the functional
relevance of changes in proteins (proteome). A recent
study has shown that RIPC cardioprotection in mice is
linked with significant changes in several phosphoproteins
associated with the z-disk area of the sarcomere [39].
Several of the phosphoproteins identified do not have
antibodies available, thus making it difficult to measure
using conventional methods. Therefore, we shall use these
methods to screen for protein activation.
Markers in blood samples
Inflammation, systemic oxidative and metabolic stress
associated with surgery will be assessed by measuring
the plasma concentration of key biomarkers. These
are 8-isoprostane, malondialdehyde (MDA) (markers ofoxidative stress), IL-6, IL-8, IL-10, TNFα (markers of
inflammation), and plasma lactate and blood pH (markers
of anaerobic stress).
Other outcomes
Operative details and clinical outcome data will be
collected for all participants. These will include aortic
cross clamp and bypass time, ICU and hospital stay,
inotropic support (quantity and duration), need for
IABP, incidence of arrhythmia, myocardial infarction and
routine measurements of serum creatinine to assess the
impact of RIPC on renal function. Adverse events will also
be recorded.
Measurement of outcomes
Blood samples
Seven blood samples will be collected from each partici-
pant: two samples will be collected before the sternonotomy
is performed and before CPB (one before RIPC and one
after RIPC) is started, and five post-operative samples will
be collected at 6, 12, 24, 48 and 72 hours after the end of
ischaemic cardioplegic arrest. Each sample will amount to
approximately 10 ml of blood stored in separate vials for
plasma and serum analysis.
Serum concentration of Troponin I will be measured
using automated assays. Plasma concentrations of IL-6,
IL-8, IL-10 and TNFα will be measured using enzyme-
linked immunosorbent assays (ELISA) or enzyme immuno-
assay (EIA) as described previously [42]. ATP catabolites,
MDA, lactate and other relevant metabolites in plasma will
be measured using HPLC and enzymatic kits as described
above. In addition, plasma lactate and blood pH will be
monitored at the same time points to determine the extent
of systemic metabolic stress.
Ventricular biopsies
Four ventricular biopsies will be collected from each
participant. Biopsies will be collected in pairs, using a
Tru-cut™ needle to obtain one biopsy from the apex of
the left ventricle and one biopsy from the anterior wall
of the right ventricle; the biopsies will be ‘snap’ frozen in
liquid nitrogen and transferred to -80°C until processing.
The first pair of biopsies will be collected after harvesting
the mammary artery and before starting CPB. The second
pair of biopsies will be collected 20 minutes after the end
of ischaemic cardioplegic arrest.
Metabolites will be measured using HPLC or commer-
cially available kits with the standard protocols established
in our laboratories [43,44]. Western blotting will be used
to determine the effect of RIPC and cardioplegic arrest on
the activation of key proteins involved in the regulation of
the MPTP (that is, ERK1/2, GSK3β, Akt). Signalling
pathways linked to these enzymes will also be moni-
tored. Appropriate antibodies will be used to detect
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In addition to protein expression, mRNA for all relevant
proteins will be determined, and the results validated [45].
The cardiac proteome and phospho-proteome will be
studied using isobaric tandem mass tagging and ana-
lysed by reverse phase nano-liquid chromatography/
mass spectrometry.
The schedule of data collection is outlined in Table 1.
Data handling and storage
Data handling
Data will be entered onto a database designed specifically
for the purpose, and data validation and cleaning will be
carried out throughout the trial. Standard operating pro-
cedures (SOPs) for database use, data validation and data
cleaning will be available and regularly maintained.
Trial data will be submitted directly into the database,
which will be accessed via the NHS portal.
Data storage
All study documentation will be retained in a secure
location during the conduct of the study and for 10 years
after the end of the study, when all patient identifiable
paper records will be destroyed by confidential means.
Prior to destruction, paper records will be scanned and
stored on the NHS server with limited password
controlled access. Where trial-related information is
documented in the medical records, these records will
be identified by a label bearing the name and duration of
the trial. Relevant ‘meta’-data about the trial and the
full dataset, but without any participant identifiers
other than the unique participant identifier, will be
held indefinitely (Imperial College London server). A
secure electronic ‘key’ with a unique participant identifier,
and key personal identifiers (for example, name, date of
birth and NHS number) will also be held indefinitely, but
in a separate file and in a physically different location
(NHS hospital server).Table 1 Data collection
Two ventricu
Pre-op
before RIPC
Immediately after RIPC
Immediately before CPB ✓
20 minutes after the end of ischemic cardioplegic arrest ✓
6 hr postop*
12 hr postop*
24 hr postop*
48 hr postop*
72 hr postop*
*postop = end of ischemic cardioplegic arrest. CPB, cardiopulmonary bypass; RIPC, rParticipant follow-up
Participants will be followed-up three months after their
operation. They will be sent a questionnaire to capture the
occurrence of any serious adverse events. Information
about any hospitalization will be requested from the
participant’s GP or the admitting hospital. Active partici-
pation in the trial terminates once the participant
completes the follow-up questionnaire and sends it back
to the research team.
Sample size
Cardiac Troponin I is measured at the start of the
operation (before RIPC or sham RIPC), after applying
RIPC or sham RIPC, and five times after the end of
ischaemic cardioplegic arrest and CPB. Determining
an appropriate sample size requires several parameters to
be specified. We have estimated some parameters from
our previous research: average pre-post correlation = 0.3
and average post-post correlation = 0.5. We propose to
recruit 30 patients/group in each surgical stratum, giving
a sample size of 60 per surgical stratum and a total of 120.
This sample size for each stratum is similar to that used in
a previous trial in which RIPC was observed to have
induced significant cardio-protection during CABG
surgery [8]. Assuming an analysis of variance and covari-
ance, this sample size will have 90% power to detect a
standardised difference in serum markers of 0.43 between
groups providing that there is no interaction between
intervention/control and pathology. If there is an
interaction, the sample size of 60 for each pathology
will have 80% power to detect a standardised difference in
serum markers of 0.55 between groups within each
pathology stratum.
Assuming again an analysis of variance and covariance
but without repeated measures, the sample size of 60 per
group (assuming no interaction between intervention/
control and pathology) will have 90% power to detect a
standardised difference in cellular markers of 0.6 betweenlar biopsies Blood samples Participant’s characteristics
✓
✓
✓
✓
✓
✓
✓
✓
emote ischaemic preconditioning.
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have 80% power to detect a standardised difference in
cellular markers of 0.72 between groups within each
pathology stratum. Based on our previous research ana-
lysing myocardial biopsies, differences of this magnitude
are plausible [46-49].
Statistical analyses
Plan of analysis
Continuous outcomes will be summarised and presented
graphically as geometric means and standard errors,
assuming that a natural logarithmic transformation will be
applied to the data to normalise their distributions [50].
The primary outcome, Troponin-I, and the secondary
outcomes such as markers of kinase activity, oxidative
stress and inflammation, are all measured multiple times
in each patient (see Table 1). Therefore, Troponin-I and
the other markers will be analysed by fitting multilevel
mixed effect linear regression models, which consider the
repeated measures in an appropriate and efficient manner.
These models will fit both fixed effects (intervention,
surgical stratum, centre, time and the interactions of
intervention x time and intervention x centre) and a
random effect. The fixed effects are analogous to
standard regression coefficients and are estimated directly.
The random effect is not directly estimated but is summa-
rized according to its estimated variances and covariance.
Baseline (pre-intervention) measures, where available, will
be analysed jointly with the post-intervention measure(s).
The interaction of group and surgical stratum will be
tested and, if statistically significant at the 10% level,
the treatment effect will be reported for each stratum
separately; otherwise, an overall treatment effect will
be given. Similarly, interactions of group and time
and group and centre, will be explored (overall or
within stratum depending on the significance of the group
by stratum interaction) and, if statistically significant at
the 10% level, the treatment effect will be reported for
each time point separately.
Analyses will be adjusted for stratification factors,
namely surgical procedure and centre. Findings will be
reported as effect sizes with 95% confidence intervals.
Analyses will be based on the intention-to-treat; cross-overs
are expected to be rare. The frequencies of complications
and conversions will be tabulated descriptively, by
pathology. However, the trial is not powered to detect
differences in adverse events and no statistical com-
parisons will be carried out.
It is important to emphasise that analyses of all outcomes
will adjust for baseline levels of outcomes. Therefore,
although there will be heterogeneity between patients
within groups, the analyses will take this heterogeneity
into account by quantifying the effects of the design
factors after removing variation attributable to individualparticipants. This approach extends to the analyses of the
proteome/phosphoproteome since data will be available
for biopsies from the same ventricle of the same par-
ticipant before and after cardioplegic ischaemic arrest.
In effect, this allows us to focus on detecting changes in
the same tissue (left or right ventricle) in two different
pathologies.
Subgroup analyses
No sub-group analyses are planned other than those
described above.
Frequency of analyses
The primary analysis will take place when follow-up is
complete for all recruited patients. No formal interim
analysis is planned. Given the nature of the intervention,
we do not propose to have a formal Data Monitoring and
Safety Committee (DMSC). We will report unexpected
serious adverse events and deaths to the trial Sponsor. In
these reports, the data will be presented by group but the
allocation will remain masked, unless we are requested to
disclose allocation because of concern about safety.
Changes to the protocol since first approved
Substantial and minor amendments have been made.
Inclusion and exclusion criteria have been amended
to include a wider age range of patients and to facilitate
recruitment. The primary outcome was changed from
Troponin T to Troponin I because the coordinating
centre measures Troponin I routinely. The type of blood
sample collection was clarified in terms of distinguishing
between serum and plasma concentrations. Anaesthetic
details were removed to allow the operating team to
follow their local practice. A more complete list of
expected adverse events was added. Novel proteomic
analyses on biopsies collected in a subgroup of participants
have been added to characterise potential mechanistic
pathways for RIPC. The sample size was increased by 25%
to allow the proteomic analyses to be carried out in a
subset of participants and to allow the trial to detect
a smaller target difference between groups within each
surgery stratum separately. The current version of the
protocol is version 3 dated 17 July 2014.
Measures to reduce the risk of bias
The trial has been designed to minimise the risk of bias.
The trial is randomised, with stratification by centre
and surgical stratum, so it is at low risk of allocation
bias/confounding. Randomisation is unlikely to be
subverted because random allocations are only issued
after participants’ identity and eligibility are confirmed
and securely documented. Blocked allocation could
increase the risk of subversion bias, but this risk is
being minimised by using varying block size. In order
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all allocations (across all surgeons) up to a particular
timepoint; since different research nurses administer the
intervention for different participants, this scenario would
require collusion between research nurses.
The trial is at some risk of attrition bias because
patients can decide to withdraw after randomisation
or the care team could decide to withdraw them.
However, we will try to minimise the probability of
attrition bias by randomising the patient at a time close to
the intervention. In addition, patients may not complete
the follow-up questionnaire after discharge. We do not
anticipate that attrition will be different between groups.
The trial is at low risk of ascertainment bias (outcome
assessment) because the outcomes are objective and the
analysts measuring blood or cellular markers are blinded
to the allocation. Blinding of patients, the clinical care staff
and the research team collecting the data, minimises risk
of performance and detection biases. Success of blinding
of patients will be assessed in the follow-up questionnaire.
Risk of bias in analysing the trial data is also low
because analyses will be done according to a pre-specified
statistical analysis plan and with an intention-to-treat basis.
Dissemination of findings
The findings will be disseminated by usual academic
channels, that is, presentation at international meetings,
as well as by peer-reviewed publications and through
patient organisations and newsletters to patients, where
available. As the study compares surgical techniques no
commercially exploitable findings are anticipated.
Discussion
What the study will investigate
We hypothesise that RIPC will reduce myocardial injury
and reduce inflammation following heart surgery and
that this effect will be greater in participants having AVR
than in those having CABG. The effects of RIPC have
been investigated in several trials to date, but their
results have been inconsistent. By measuring many
markers in myocardial biopsies and in blood samples, at
different times after administering RIPC or sham RIPC,
we expect to be able to relate changes in potential
signalling mechanisms to the extent of myocardial injury
measured by troponin I.
Study design
The study design is a two-centre, randomised controlled
trial with patients (CABG or valve) being randomly
assigned to receive RIPC or control (sham RIPC) just
before the surgery. This study design follows the one
used in ERICCA [19]. Before this study commenced,
we had discussions with the ERICCA trial team, and
we tried to have our study as a sub-study to ERICCA.This was not possible because of the need for substantial
protocol and governance changes, which were difficult to
implement in a large ongoing multicentre study.
Nevertheless, we adopted the same intervention and
comparator. Our study population, however, is different;
ERICCA is recruiting patients having CABG (with or
without valve surgery) with an additive Euroscore greater
than or equal to 5, whereas we have deliberately recruited
patients undergoing CABG only or AVR only (regardless
of their Euroscore). These differences in the trial popula-
tions meant that both centres taking part in this trial have
also recruited to ERICCA at the same time.
Challenges in study procedures
It has been suggested that some drugs interact with remote
ischaemic preconditioning. Propofol and Fluorane, two
of the most commonly used drugs in anaesthetic practice,
are two such drugs. Propofol may inhibit STAT-5 tran-
scription [51], hence reducing the preconditioning effect,
while Fluorane may enhance protection [52]. However,
there is a lack of firm evidence to substantiate these
potential effects on the ischaemic preconditioning path-
way. Therefore, for consistency, we have opted for the
strategy of the ERICCA trial, which does not specify an
anaesthetic protocol and allows each centre to follow its
own practice. The two centres recruiting to this study
adhere to their own, well-documented centre-specific
protocols, minimizing variability in the anaesthetic proce-
dures used between patients at the same centre. Stratified
randomization ensures that patients allocated to both the
intervention and control group within a centre will undergo
the same anaesthetic procedures. Moreover, we will be able
(albeit with low statistical power) to describe the interaction
between centre and intervention.
Despite being a two-centre study, this study will recruit
CABG patients at only one centre (ICHT). This is because
the cardioplegia protocol for this operation differs between
the two centres (warm blood versus cold blood), and it is
believed that this might influence selected outcomes. This
is hindering the recruitment rate, together with the
challenges in recruiting patients to the AVR group in both
centres because AVR operations are less frequent.
The intervention is carried out primarily in the anaes-
thetic room. Blinding of the operating team and carrying
out the intervention can be challenging at this stage of the
study because it coincides with the pre-operative anaesthetic
procedures. The time a patient spends in the anaesthetic
room can vary, and on some occasions the intervention can
be incomplete by the time the patient is ready for theatre.
To prevent delay of surgery, the intervention is completed
in theatre as the patient is being prepared for surgery before
sternotomy.
In order to monitor the changes in biomarker outcomes,
blood samples are collected at various time points during
Fiorentino et al. Trials  (2015) 16:181 Page 9 of 10a participant’s hospital stay. Some of these blood sample
collections are scheduled outside office working hours.
Even though reminders about the need to collect these
samples are ‘handed over’ to the clinical team in charge of
the patient when shifts change, on some occasions sample
collection may be missed due to lack of time and other
priorities. Similarly, there may be instances in which the
biopsies are not collected; we aim to minimise this risk by
having a member of the research team present in the
theatre to prompt the operator to take the biopsies.Trial status
The trial opened for recruitment in one centre (ICHT)
in February 2013 and in the other centre (UH Bristol) in
June 2013. Recruitment is ongoing.Additional file
Additional file 1: Patient consent form. Form used to obtain consent
from patients.Abbreviations
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